Effects of Increased Greek Yogurt Consumption in Senior Adults
NCT Number: NCT06530394
Status: NOT_YET_RECRUITING
Study Type: INTERVENTIONAL
Phases: NA
Conditions: Osteoporosis|Inflammation
Interventions: DIETARY_SUPPLEMENT: Greek yogurt
Sponsor: Brock University
Sex: ALL
Age: ADULT, OLDER_ADULT
Enrollment: 60
Study Design: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
Start Date: 2024-08-10
Completion Date: 2027-04-30
Locations: Brock University, St. Catharines, Ontario, L2S 3A1, Canada

Summary:
This study aims to examine whether Greek yogurt (GY) consumption will lead to beneficial changes in bone metabolism and inflammation, in senior adults, male and female, when combined with regular exercise (senior fit classes; GYEX) and without exercise (GYNE). It is hypothesized that compared to a control group (senior fit classes, no GY; NYEX), an 8-week GY consumption intervention in senior adults with and without exercise will lead to positive effects on body composition, and markers of bone metabolism and inflammation such that the anabolic and anti-inflammatory markers of these physiological processes will increase more than any training-induced catabolic and pro-inflammatory markers (i.e., more than measures observed in the NYNE group).

Primary Outcome Measures: Serum concentrations of osteocalcin, Bone turnover marker measured in picograms/milliliter of serum (pg/mL), Weeks 0 and 8|Serum concentrations of amino-terminal propeptide of type I collagen (P1NP), Bone formation marker measured in pg/mL, Weeks 0 and 8|Serum concentrations of C-telopeptides of type I collagen (CTX), Bone resorption marker measured in ng/mL, Weeks 0 and 8|Serum concentrations of osteoprotegerin (OPG), Regulator of bone remodelling (osteokine) measured in pg/mL, Weeks 0 and 8|Serum concentrations of sclerostin, Regulator of bone remodelling (osteokine) measured in pg/mL, Weeks 0 and 8|Serum concentrations of receptor activator of nuclear factor kappa-Β ligand (RANKL), Regulator of bone remodelling (osteokine) measured in pg/mL, Weeks 0 and 8|Serum concentrations of parathyroid hormone (PTH), Regulator of bone remodelling measured in pg/mL, Weeks 0 and 8|Plasma concentrations of interleukin-6 (IL6), Inflammatory cytokine measured in pg/mL, Weeks 0 and 8|Plasma concentrations of interleukin-10 (IL10), Anti-inflammatory cytokine measured in pg/mL, Weeks 0 and 8|plasma concentrations of inflammatory cytokines, including interleukin-6 (IL6), interleukin-10 Plasma concentrations of tumour necrosis factor-alpha (TNFα), Pro-inflammatory cytokine measured in pg/mL, Weeks 0 and 8|Serum concentrations of irisin, Myokine measured in pg/mL, Weeks 0 and 8|Serum concentrations of insulin-like growth factor 1 (IGF1), Growth factor measured in pg/mL, Weeks 0 and 8
Secondary Outcome Measures: Body mass, Body mass in kilograms (kg) using bioelectrical impedance analysis, Weeks 0 and 8|Body composition, fat-free mass and fat mass in kg measured by bioelectrical impedance analysis, Weeks 0 and 8|Height, Height measured in centimeters with a stadiometer, Weeks 0 and 8|Energy intake and expenditure, Food Frequency and Activity Questionnaire, Weeks 0 and 8|Sport-Specific Nutrition Knowledge Questionnaire (GeSNK), A standardized questionnaire including 64 items assessing general and sport-specific nutrition knowledge., Weeks 0 and 8